Carbamazepine (Epilepsy) updated on 04-22-2025

Preeclampsia

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S8082
R24686		 Aydin (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2020 Preeclampsia/ eclampsia throughout pregnancy retrospective cohort exposed to other treatment, sick excluded Adjustment: No 0.45 [0.01;25.16] C
excluded (control group) 		0/15   0/7 0 15
ref
S8074
R24634		 Aydin (Carbamazepine) (Controls unexposed, sick), 2020 Preeclampsia/ eclampsia throughout pregnancy retrospective cohort unexposed, sick Adjustment: No 1.48 [0.03;79.05] C 0/15   0/22 0 15
ref
S8145
R25039		 Cohen (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2019 Preeclampsia early pregnancy retrospective cohort (claims database) exposed to other treatment, sick excluded Adjustment: Yes 1.10 [0.58;2.09]
excluded (control group) 		-/-   -/- - -
ref
S8141
R25011		 Cohen (Carbamazepine) (Controls unexposed NOS), 2019 Preeclampsia early pregnancy retrospective cohort (claims database) unexposed (general population or NOS) Adjustment: Yes 1.24 [0.58;2.69] -/-   53,634/1,440,631 - -
ref
S6282
R16916		 Borthen (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2011 Pre-eclampsia during pregnancy (anytime or not specified) retrospective cohort exposed to other treatment, sick excluded Adjustment: No 0.31 [0.06;1.67] C
excluded (control group) 		2/28   6/30 8 28
ref
S6276
R16892		 Borthen (Carbamazepine) (Controls unexposed, disease free), 2011 Pre-eclampsia during pregnancy (anytime or not specified) retrospective cohort unexposed, disease free excluded Adjustment: No Matched 1.40 [0.30;6.50]
excluded (control group) 		2/28   11/205 13 28
ref
S6279
R16904		 Borthen (Carbamazepine) (Controls unexposed, sick), 2011 Pre-eclampsia during pregnancy (anytime or not specified) retrospective cohort unexposed, sick Adjustment: No 0.55 [0.11;2.62] C 2/28   11/89 13 28
ref
Total 3 studies 1.07 [0.54;2.11] 13 43
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Aydin (Carbamazepine) (Controls unexposed, sick), 2020Aydin, 2020 1 1.48[0.03; 79.05]0153%ROB confusion: criticalROB selection: criticalROB classification: moderateROB missing: lowROB mesure: moderateROB reporting: moderate Cohen (Carbamazepine) (Controls unexposed NOS), 2019Cohen, 2019 2 1.24[0.58; 2.69]--78%ROB confusion: moderateROB selection: lowROB classification: moderateROB missing: unclearROB mesure: moderateROB reporting: moderate Borthen (Carbamazepine) (Controls unexposed, sick), 2011Borthen, 2011 3 0.55[0.11; 2.62]132819%ROB confusion: criticalROB selection: moderateROB classification: moderateROB missing: lowROB mesure: moderateROB reporting: moderate Total (3 studies) I2 = 0% 1.07[0.54; 2.11]13430.25.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Carbamazepine) (Controls unexposed, sick; 2: Carbamazepine) (Controls unexposed NOS; 3: Carbamazepine) (Controls unexposed, sick;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.07[0.54; 2.11]13430%NAAydin (Carbamazepine) (Controls unexposed, sick), 2020 Cohen (Carbamazepine) (Controls unexposed NOS), 2019 Borthen (Carbamazepine) (Controls unexposed, sick), 2011 3 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.24[0.58; 2.67]-- -NACohen (Carbamazepine) (Controls unexposed NOS), 2019 1 unexposed, sickunexposed, sick 0.62[0.14; 2.69]13430%NAAydin (Carbamazepine) (Controls unexposed, sick), 2020 Borthen (Carbamazepine) (Controls unexposed, sick), 2011 2 Tags Adjustment   - No  - No 0.62[0.14; 2.69]13430%NAAydin (Carbamazepine) (Controls unexposed, sick), 2020 Borthen (Carbamazepine) (Controls unexposed, sick), 2011 2   - Yes  - Yes 1.24[0.58; 2.67]-- -NACohen (Carbamazepine) (Controls unexposed NOS), 2019 1 All studiesAll studies 1.07[0.54; 2.11]13430%NAAydin (Carbamazepine) (Controls unexposed, sick), 2020 Cohen (Carbamazepine) (Controls unexposed NOS), 2019 Borthen (Carbamazepine) (Controls unexposed, sick), 2011 30.25.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 6282, 6276, 8145, 8082

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.27[0.64; 2.52]53,638280%NACohen (Carbamazepine) (Controls unexposed NOS), 2019 Borthen (Carbamazepine) (Controls unexposed, disease free), 2011 2 unexposed, sick controlsunexposed, sick controls 0.62[0.14; 2.69]13430%NAAydin (Carbamazepine) (Controls unexposed, sick), 2020 Borthen (Carbamazepine) (Controls unexposed, sick), 2011 2 exposed to other treatment, sick controlsexposed to other treatment, sick controls 0.91[0.49; 1.69]8431%NAAydin (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2020 Cohen (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2019 Borthen (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2011 30.510.01.0